Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena

[News]

Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.

More... (http://www.news-medical.net/news/20100707/Crux-Biomedical-commences-enrollment-in-Retrieve-2-pivotal-US-IDE-trial-of-new-Vena-Cava-Filter.aspx)